To the full analysis
MedCap stock: growth
MCAP.STMedCap reported $211.37M in revenue for fiscal 2025, up 16.7% on the prior year, up 20.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
15.2%
per year from 2007 to 2025, per share 13.5%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2014 | since 2007 | |
|---|---|---|---|
| Revenue | 20.9% | 9.5% | 15.2% |
| Revenue per share | 19.8% | 8.2% | 13.5% |
| Earnings | 29.3% | 38.4% | no data |
| Earnings per share | 28.2% | 37.7% | no data |
| Free cash flow | 25.2% | no data | no data |
| Free cash flow per share | 24.1% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $18.94M | −$774.8K | −$468.47K |
| 2008 | $18.76M | $11.43K | −$293.19K |
| 2009 | $25.95M | $581.27K | $24.37K |
| 2010 | $31.67M | $1.35M | $1.67M |
| 2011 | $33.74M | $1.07M | $896.63K |
| 2012 | $35M | $1.72M | $2.02M |
| 2013 | $82.83M | $2.27M | −$2.47M |
| 2014 | $85.51M | $854.71K | −$1.53M |
| 2015 | $81.91M | $1.95M | −$2.83M |
| 2016 | $85.4M | $7.32K | $4.49M |
| 2018 | $71.09M | $60.16K | $5.66M |
| 2019 | $75.92M | $5.38M | $4.12M |
| 2020 | $81.96M | $6.11M | $9.14M |
| 2021 | $91.88M | $9.68M | $5.56M |
| 2022 | $111.44M | $11.79M | $4.13M |
| 2023 | $159.17M | $17.27M | $18.92M |
| 2024 | $181.17M | $20.8M | $29.46M |
| 2025 | $211.37M | $22.04M | $28.13M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 26 Jun 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.